SIMPATHIC Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular disorders by exploiting SIMilarities in clinical and molecular PATHology
- Coordinator
- Stichting Radboud Universitair Medisch Centrum, Netherlands
- Runs
- 1 July 2023 to 30 June 2028
- Status
- Running
- EU funding
- €8.8m
- Total cost
- €8.8m
- Partners
- 21 organisations in 10 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101080249
What the project is doing
In the project's own words, from its summary on CORDIS.
Drug repurposing can fill an important gap for rare disease patient groups with large unmet medical needs. In comparison to traditional drug development, drug repurposing reduces the time and costs for drug development, regulatory approval, and market authorization. Yet, we need to increase the efficiency of the drug repurposing pathway to provide broader access to new therapeutic modalities for larger groups of patients.
SIMPATHIC’s main objective is to accelerate drug repurposing for rare neurological, neurometabolic and neuromuscular disorders. SIMPATHIC’s main accelerating innovation is the simultaneous drug development for groups of patients with different genetic diagnoses but overlapping neurological symptoms and molecular pathomechanisms. SIMPATHIC’s key outputs accelerating the drug repurposing pathway include: Standard operating procedures for culturing stem cell-derived neuronal cell models with proven relevance for clinical symptoms and amenable to high-throughput drug screens; New drug repurposing candidates with proven efficacy in advanced brain-on-a-chip and 3D brain organoid models, as demonstrated by reversal of molecular biomarker signatures and cellular readouts associated with clinical symptoms; Designs of innovative basket clinical trials to which patients with different disorders are recruited, utilizing and aggregating personalized clinical endpoints; A training module for patients and patient organizations to empower them as drivers of the drug repurposing pathway; Blueprints for intellectual property strategies, business models, regulatory dossiers and patient access strategies, developed in co-creation between all relevant stakeholders.
SIMPATHIC’s proof-of-concept for the simultaneous development of repurposed drugs for multiple indications will show the path forward to development of personalized treatment opportunities for groups of rare disease patients in a cost- and time-efficient manner.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Coordinator |
| Children's Hospital of Eastern Ontario Research Institute Inc | Ottawa | Canada | Participant |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Participant |
| Heinrich-Heine-Universitaet Duesseldorf | Dusseldorf | Germany | Participant |
| Universitatsklinikum Heidelberg | Heidelberg | Germany | Participant |
| A. Persidis & Sia Oe | Athina | Greece | Participant |
| Elpen Pharmaceutical Co Inc | Pikermi | Greece | Associatedpartner |
| National Center for Scientific Research ""demokritos"""" | Agia Paraskevi | Greece | Participant |
| Fair Data Systems SL | Madrid | Spain | Participant |
| Apteeus | Lille | France | Participant |
| Euro-Dyma | Paris | France | Participant |
| Fondation Maladies Rares | Paris | France | Participant |
| Universite Du Luxembourg | Esch-Sur-Alzette | Luxembourg | Participant |
| Eatris Eric | Amsterdam | Netherlands | Participant |
| International Mito Patients | Baarn | Netherlands | Participant |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Participant |
| Stichting Eupati Foundation | Utrecht | Netherlands | Participant |
| Faculdade de Farmácia da Universidade de Lisboa | Lisboa | Portugal | Participant |
| Univerza V Ljubljani | Ljubljana | Slovenia | Participant |
| Euro-Ataxia | London | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI